

REMARKS

Claims 38-46, 50-51, 53-58, and 63-68 are canceled herein in response to the restriction requirement, and not for reasons pertaining to patentability.

No new matter is added. Entry of this amendment is respectfully requested.

Restriction Requirement

In response to the restriction requirement, Applicants elect Group I (claims 35-37, 47-49, 52, and 59-62), drawn to rhesus rhadinovirus (RRV), and compositions or oligonucleotides thereof, and to a method of using the virus to produce an immunocompromised model of RRV infection, with traverse. Group I includes the virus sequence, and as such, includes nucleic acid sequences encoding all of the proteins of the RRV. Thus, applicants submit that it would not be an undue burden on the examiner to search the subject matter of Group III (claims 42-46, and 49-52, drawn to a nucleic acid encoding a protein of RRV) with the subject matter of Group I. However, solely to advance prosecution of the subject application, claims 38-46, 50-51, and 53-58 and 63-68 are canceled herein.


CONCLUSION

If any minor matters remain to be addressed before substantive examination of the application, the examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446